"The Phase II and III clinical trials for aerosolized liposomal amikacin or ciprofloxacin for the treatment of P. aeruginosa lung infections in CF and non-CF bronchiectasis patients are evidence that demonstrate that in the next few years the liposome-based antibiotic-delivery systems will prove to be remarkable treatment alternatives for infectious diseases. For P. aeruginosa lung infections, the inhalational route of administration of liposomal antibiotic formula- tions has the potential to increase patient compliance, reduce the duration of the antibiotic treatment and possibly decrease the likelihood of bacterial resistance. The unique properties of liposomes will provide many opportunities to develop a wide range of liposomes to offer a clinically proven, biocompatible versatile plat- form for the enhancement of pharmacological efficacy of antibiotics. It is anticipated that in the next few years, liposomes may be used to deliver a combination of anti- biotic agents (i.e., aminoglycoside and β-lactam) or an antibacterial agent and an inhibitor of a major resistance mechanism (i.e., β-lactam and β-lactamase inhibitor). Also, liposomes that specifically target bacterial cells may be engineered by attaching amino acid fragments, such as antibodies or proteins or appropriate fragments that target specific sites in bacteria. It is envisioned that the future of liposomal antibiotic development is bright with a number of these lipid-based products proving to be remarkable treatment alternatives in the treatment of P. aeruginosa lung infections. "